Abstract
The purpose of the present study was to investigate the impact of the use of peripheral blood progenitor cells (PBPCs) on the induction of autologous graft-versus-host disease (GVHD) in patients with advanced breast cancer. 14 women with stage IIIB and 36 women with stage IV breast cancer received cyclosporine (CsA) 2.5 mg kg–1 i.v. daily, d 0–28, and interferon-gamma (IFNg) 0.025 mg/m2 s.c. qod, d7–28, following PBPC-T ± bone marrow transplantation (BMT). Preceding high-dose chemotherapy consisted of cyclophosphamide 6 g/m2 and thiotepa 800 mg/m2. Histologically proven ≥grade II cutaneous GVHD was induced in 18/50 (36%) of patients and was independent of the source of haematopoietic support. in vitro studies showed that post-transplant, 76% of patients had developed auto-cytotoxicity against their own pre-transplant PHA-lymphoblasts. A significant correlation between the occurrence of GVHD ≥grade II and cytolysis was observed in the NK cell-line K562 and the T47D breast cancer cell-line. With a median follow-up of 2½ years, the overall survival (OS) is 58%, the disease-free survival (DFS) 26%, both independent of the development of GVHD and similar to what has been observed in other studies on high-dose chemotherapy in advanced breast cancer. It therefore remains unclear whether the induction of autologous GVHD with the occurrence of auto-cytotoxic lymphocytes can result in an anti-tumour effect in this group of patients. © 2000 Cancer Research Campaign http://www.bjcancer.com
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Antman KH, Rowlings PA, Vaughan WP, Pelz CJ, Fay JW, Fields KK, Freytes CO, Gale RP, Hillner BE, Holland HK, Kennedy MJ, Klein JP, Lazarus HM, Mc Carthy PL, Saez R, Spitzer G, Stadtmauer EA, Williams SF, Wolff S, Sobocinski KA, Armitage JO and Horowitz MM (1997 High-dose chemotherapy with autologous hematopoietic stem-cell support for breast cancer in North America. J Clin Oncol 15: 1870–1879
Bartek J, Petrek M, Vojtesek B, Bartkova J, Kovarik J and Rejthar A (1987 HLA-DR antigens on differentiating human mammary gland epithelium and breast tumours. Br J Cancer 56: 727–733
Basade MM and Gulati SC (1998 High-dose chemotherapy in metastatic breast cancer. Lancet 351: 386–387
Bauer DJ, Hood AF and Horn TD (1993 Histologic comparison of autologous graft-versus-host reaction and cutaneous eruption of lymphocyte recovery. Arch Dermatology 129(7): 855–858
Bezwoda WR, Seymour L and Dansey RD (1995 High-dose chemotherapy with hematopoietic rescue as primary treatment for metastatic breast cancer: a randomized trial. J Clin Oncol 13: 2483–2489
Busch R and Mellins ED (1996 Developing and shedding inhibitions: how MHC Class II molecules reach maturity. Curr Opin Immunol 8: 51–58
Chao NJ, Schriber JR, Grimes K, Long GD, Negrin RS, Raimondi CM, Horning SJ, Brown SL, Miller L and Blume KG (1993 Granulocyte colony-stimulating factor “mobilized” peripheral blood progenitor cells accelerate granulocyte and platelet recovery after high-dose chemotherapy. Blood 81: 2031–2035
Cooper MH, Hartman GG and Starz TE (1991 The induction of pseudo-graft-versus-host disease following syngeneic bone marrow transplantation using FK506. Trans Proc 23: 3234–3235
Fischer AC and Hess AD (1990 Age related factors in Cyclosporine-induced syngeneic graft-vs-host disease: Regulatory role of marrow derived T lymphocytes. J Exp Med 172: 85–94
Fischer AC, Ruvolo P and Burt R (1995 Characterization of the autoreactive T cell repertoire in cyclosporine-induced syngeneic graft-versus-host disease: a highly conserved repertoire mediates autoaggression. J Immunol 154: 3713–3725
Fuchs EJ, Bedi A, Jones RJ and Hess AD (1995 Cytotoxic T cells overcome BRL-ABL-mediated resistance to apoptosis. Cancer Res 55: 463–466
Ghayur T, Seemayer TA and Lapp WS (1987 Kinetics of natural killer cell cytotoxicity during the graft-versus-host reaction: Relationship between natural killer cell activity, T and B cell activity, and development of histopathological alterations. Transplantation 44: 254–260
Glazier A, Tuschka PJ, Farmer ER and Santos GW (1983 Graft-versus-host disease in cyclosporin A treated rats after syngeneic and autologous bone marrow reconstitution. J Exp Med 158: 1–8
Glucksberg H, Storb R and Fefer A (1974 Clinical manifestations of graft versus host disease in human recipients of marrow from HLA matched sibling donors. Transplantation 18: 295–304
Hess AD, Fischer AC and Beschorner WE (1990 Effector mechanisms in cyclosporine A-induced syngeneic graft-versus-host disease. J Immunol 145: 526–533
Hess AD, Bright EC, Thoburn C, Vogelsang GB, Jones RJ and Kennedy MJ (1997 Specificity of effector T lymphocytes in autologous graft-versus-host disease: role of the major histocompatibility complex class II invariant chain peptide. Blood 89: 2203–2209
Hess A, Thoburn C, Bright E and Horwitz L (1998 Specificity of effector mechanisms in syngeneic graft-vs-host disease: recognition of the MHC class II invariant chain peptide (CLIP). Transplant Proc 29: 725–727
Hess AD, Thoburn CJ, Chen W and Horwitz L (2000 Complexity of effector mechanisms in Cyclosporine-induced syngeneic graft-vs-host disease. Biology of Blood and Marrow. Transplantation 6: 13–24
Horn TD, Bauer DJ, Vogelsang GB and Hess AD (1994 Reappraisal of histologic features of the acute cutaneous graft-versus-host reaction based on an allogeneic rodent model. J Invest Dermato 103(2): 206–210
Jones RJ, Hess AD, Mann RB, Piantadosi S, Vogelsang GB, Farmer ER, Geller RB and Santos GW (1989 Induction of graft-versus-host disease after autologous bone marrow transplantation. Lancet 1: 754–757
Kahan BD (1982 Cyclosporine. N Engl J Med 21: 1725–1738
Kennedy MJ, Vogelsang GB, Beveridge RA, Farmer ER, Altomonte V, Huelskamp AM and Davidson NE (1993 Phase I trial of intravenous cyclosporine to induce graft-versus-host disease in women undergoing autologous bone marrow transplantation for breast cancer. J Clin Oncol 11: 478–484
Kennedy MJ, Vogelsang GB, Jones RJ, Farmer ER, Hess AD, Altomonte V, Huelskamp AM and Davidson NE (1994 Phase I trial of Interferon gamma to potentiate cyclosporine-induced graft-versus-host disease in women undergoing autologous bone marrow transplantation for breast cancer. J Clin Oncol 12: 249–257
Miura Y, Nakao S, Veda M, Zeng W, Wang H, Takami A, Yamazaki H, Kawamura Y and Shiobara, (2000 Autologous graft-versus-host disease with cyclosporin A after peripheral blood transplantation: Analysis of factors affecting induction. J Allergy and Clin Immunol (in press),
Ruvolo P, Bright E, Kennedy MJ, Morris LE, Fischer AC, Vogelsang GB, Jones RJ and Hess AD (1995 Cyclosporine-induced autologous graft versus host disease: assessment of cytolytic effector mechanisms and the Vβ T-cell receptor repertoire. Transplant Proc 27: 1363–1365
Sale G, Lerner K, Barker E, Shulman HM and Thomas ED (1977 The skin biopsy in the diagnosis of acute graft-versus-host disease in man. Am J Pathol 89: 621–625
Weiden PL, Sullivan KM, Flournoy N, Storb R and Thomas ED (1980 Antileukemic effects of graft-versus-host disease. Contribution to improved survival after allogeneic marrow transplantation. N Engl J Med 304: 1529–1533
Whitford P, George WO and Campbell AM (1992 Flow cytometric analysis of tumor infiltrating lymphocyte activation and tumor cell MHC class I and II expression in breast cancer patients. Cancer Lett 61: 157–164
Zujewski J, Nelson A and Abrams J (1998 Much ado about not enough data: high-dose chemotherapy with autologous stem cell rescue for breast cancer. J Natl Cancer Inst 90: 200–209
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
van der Wall, E., Horn, T., Bright, E. et al. Autologous graft-versus-host disease induction in advanced breast cancer: role of peripheral blood progenitor cells. Br J Cancer 83, 1405–1411 (2000). https://doi.org/10.1054/bjoc.2000.1499
Received:
Revised:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1054/bjoc.2000.1499
Keywords
This article is cited by
-
Autologous graft-versus-host disease: harnessing anti-tumor immunity through impaired self-tolerance
Bone Marrow Transplantation (2008)
-
Severe intestinal graft-versus-host disease following autologous stem cell transplantation
Bone Marrow Transplantation (2006)
-
Enhancement of cyclosporin A-induced autologous graft-versus-host disease after peripheral blood stem cell transplantation by utilizing selected CD34+ cells
Bone Marrow Transplantation (2003)
-
Autologous peripheral blood stem cell transplantation with induction of autologous graft-versus-host disease in acute myeloid leukemia
Bone Marrow Transplantation (2003)
-
Role of Immunotherapy in Stem Cell Transplantation
International Journal of Hematology (2003)
